Cytokine-suppressive anti-inflammatory drugs status of development in rheumatoid arthritis

Clinical Immunotherapeutics

Volumn 6, Issue 5, 1996, Pages 395-404

  Tom, W ^a   Huizinga, J ^a   Breedveld, Ferdinand C ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AUROTHIOMALATE; CORTICOSTEROID; CYCLOSPORIN; INTERLEUKIN 10; METHOTREXATE; MONOCLONAL ANTIBODY; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLAMINE; PIROXICAM; SALAZOSULFAPYRIDINE; TENIDAP; TUMOR NECROSIS FACTOR;

CLINICAL TRIAL; HUMAN; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS;

EID: 0029806396     PISSN: 11727039     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf03259358     Document Type: Article

References (67)

1. Van der Lubbe PA, Dijkmans BAC, Markussc HM. et al. A randomized, double-blind, placebo-controlled study of CD4 monoclonal antibody therapy in early rheumatoid arthritis. Arthritis Rheum 1995; 38: 1097-106
2. Chu CQ, Field M, Allard S. et al. Detection of cytokines at the cartilagepannus junction in patients with rheumatoid arthritis: implications for the role of cytokines in cartilage destruction and repair. Br J Rheumatol 1992; 31: 653-61
3. Chen E, Keystone EC, Fish EN. Restricted cytokine expression in rheumatoid arthritis. Arthritis Rheum 1993: 36: 901-9
4. Brennan FM, Chantry D, Jackson A, et al, inhibitory effect of TNF alpha antibodies on synovial cell IL1 production in rheumatoid arthritis. Lancet 1989; II: 244-7
5. Haworth C, Brennan FM. Chantry D. et al. Expression of granulocyte-macrophage colony stimulating factor (GM-CSF) in rheumatoid arthritis: regulation by tumor necrosis factor alpha. Eur J Immunol 1991:21:2575-9
6. Keffer J, Probert L. Cazlaris H. et al. Transgenic mice expressing human tumor necrosis factor: a predictive model of arthritis"! EMBOJ 1991; 10:4025 31
7. Fong KY, Boey ML, Koh WH, et al, Cytokine concentrations in the synovial fluid and plasma of RA patients: correlation with bony erosions. Clin Exp Rheumatol 1994: 12: 55-8
8. Bathon JM, Hwang JJ, Shin LH. et al. Type IV collagen-specific mRNA is expressed by cultured synovial fibroblasts and is suppressed by IL-I. Arthritis Rheum 1994; 37: 1350 6
9. Amer EC, Tortorella MD. Signal transduction through chondrocyte integrin receptors induces matrix metalloproteina.se synthesis and synergizes with IL2. Arthritis Rheum 1995: 38: 1304-14
10. K). Wendung D, Racadot E, Wijdenes J. Treatment of severe rheumatoid arthritis by anti-lL6 mAb. J Rheumatol 1993: 20: 259 62
11. Dinarello CA, Modalities for reducing II. I activity in disease. Immunol Today 1993: 14:260-4
12. Bandara G, Mueller GM. Galea-Lauri J. et al. Intraarticular expression of biologically active IL1-RA protein by c.v i'Y
13. L,ebsack ME. Paul CC, Martindale JJ. et al. A dose and regimen ranging study of IL 1 -R A in patients with R A. Arthritis Rheum 1993: 36: S39
14. Drevlow B, Capezio J. Lovis R. et al. Phase I study of reconibinant human IL I receptor administered intraarticularly in active RA. Arthritis Rheum 1993; 36 Suppl.: S39
15. Drevlow B, Lovis R. Haag MA. Phase I study of recomhinant human IL l receptor administered subcutaneously in patients with active rheumatoid arthritis. Arthritis Rheum 1994: 37: S339
16. Elliott MJ, Maini RN, Feldmann M, et al. Randomised doubleblind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 1994; 344: 1105-10
17. Eliiott MJ, Maini RN, Anti-cytokines and cytokines in rheumatoid arthritis. Rheumatol Europe 1995: 24: 94-8
18. Garcia I, Miyazaki Y, Araki K. et al. Transgenic mice expressing high levels of s TNFRI fusion protein are protected from lethal septic shock and cerebral malaria and are highly sensitive to Lisleria monoc\loenfs and Lcishntania major infections. Eur J Immunol 1995; 25: 2401-2407
19. Moreland LW, Margolies GR, Heck IW. et al. Soluble tumor necrosis factor receptor (STNFR): results of a phase I dose escalation study in patients with rheumatoid arthritis. Arthri tis Rheum 1994: 37: S295
20. Rosenstein ED, Kunicka J, Kramer N. et al. Modification of cvtokine production by piroxicam. J Rheumatol 1994; 2l: 901-4
21. Marlieh GD, Danner RL. Ceska M. et al. Detection of IL8 and TNF in normal humans after intravenous endotoxin: the effect of anti-inflammatory agents. J Exp Med 1991; 173: 1021-4
22. Spinas GA, Bloesch D. Keller U. et al. Pretreatment with ibuprofen augments circulating TNF. IL6 and elastase during acute endoloxinemia. J Infect Dis 1991: 163: 89-95
23. Madhok R, Tenidap. Lancet 1995; 346: 481-5
24. Zhu X, Ertel W. Avala A. et al. Chloroquine inhibits macrophage TNFa mRNA transcription. Immunology I993: 80: 122-6
25. Clark P, Casas E, Tugwell P. et al. Hydroxychloroquine coin pared with placebo in rheumatoid arthritis: a randomied controlled trial. Ann Intern Med 1993: 119: 1067-77
26. Neuman PM, To SST. Robinson GM, et al. Effect of gold sodium thiomalate and its thiomalate component on the in \'i!n> expression of endothelial cell adhesion molecules. J Clin Invest 1994:94: 1864-7
27. Handel ML, Watts CKW, Defazio A. et al. Inhibition of AP-I binding and transcription by gold and selenium involving conserved cysteine residues in Jun and Fose. Proc Natl Acad Sei USA 1995:92:4497-501
28. Yanni G, Parana! MNMR, Poston RN. el al. Intramuscular gold decreases cytokine expression and macrophage numbers in the rheumatoid synovial membrane. Ann Rheum Dis 1994; 53: 256-60
29. Capell HA, Porter DR, Madhok R, et al. Second line (diseasemodifying) treatment in rheumatoid arthritis: which drug for which patient. Ann Rheum Dis 1993; 52: 423-9
30. Rains CP, Noble S. Faulds D. Sulfasalazine: a review of its pharmacological properties and therapeutic efficacy in the treatment of rheumatoid arthritis. Drugs 1995; 50: 137-56
31. Neumann VC, Taggart AJ, Le Gallez P. et al. A study to determine the active moiety of sulphasalaine in rheumatoid arthritis. J Rheumatol 1986; 13: 285-7
32. Kremer JM, The mechanism of action of melhotrexate in rheumatoid arthritis: the search continues. J Rheumatol 1994: 21: 1-5
33. Cronstein BN, Naime D, Ostad E. The antiinflammatory mechanism of methotrexate. J Clin Invest 1993; 92: 2675-82
34. Baggott JE, Vaughn WH, Hudson BB. Inhibition of 5-aminoimidazole-4-carboxamide ribotide lransformyla.se, adenosine deaminase and 5'-adenylate deaminase by polyglutamates of methotrexate and oxidized folates and by 5-aminoimidazole4-carboxamide riboside and ribotide. Biochem J 1986; 236: 193-200
35. Cronstein BN, Naime D, Firestein G. The amiinflammatory effects of an adenosine kinase inhibitor are mediated by adenosine. Arthritis Rheum 1995; 38: 1040-5
36. Firestein GS, Pain MM, Boyle DL, Mechanisms of methotrexate action in rheumatoid arthritis: selective decrease in synovial eollagenase gene expression. Arthritis Rheum 1994; 37: 193-200
37. Balsa A, Gamallo C, Martin-Mola E, et al, Histologie changes in rheumatoid synovitis induced by naproxen and methotrexate. J Rheumatol 1993; 30: 1472-77
38. Ohya N, Yamada T, Takashi K, et al, Differential effects of MTX on the proliferation and proinflammatory tytokine production of an in vitro model for human proliferative synovitis (abstract!. Arthritis Rheum 1995; 38: S265
39. Barrera P, Boerbooms AM, Demacker PN, et al, Circulating concentrations and production of cytokines and soluble receptors in RA patients: effect of a single dose of MTX. Br J Rheumatol 1994; 33: 1017-24
40. Barrera P, Boerbooms ATH, Janssen EM, et al, Circulating soluble tumor necrosis factor receptors, IL2 receptors, TNF alpha and IL6 levels in rheumatoid arthritis. Arthritis Rheum 1993; 36: 1070-9
41. Weinblatt ME, Kaplan H, Germain BF, et al, Methotrexate in rheumatoid arthritis: a five-year prospective multicenter study. Arthritis Rheum 1994; 37: 1492-8
42. Cable A, Farkas JC, Fitting C, et al, High levels of portal TNFalpha during abdominal aortic surgery in man. Cytokine 1993: 5: 448-53
43. Landewé RBM, Goei The HS, van Rijthoven AM, et al, A randomized, double-blind, 24-week controlled study of low dose cyclosporine versus chloroquine for early rheumatoid arthritis. Arthritis Rheum 1994; 37: 637-43
44. Zuckerman SH, Shellhaas J, Butler LD, Differential regulation of lipopolysaccharide-inducedinterleukin 1 and tumor necrosis factor synthesis: effects of endogenous and exogenous glucocorticosteroids and the role of the pituitary-adrenal axis. EurJImmunol 1989; 19: 301-5
45. Colding S, Emery P, Young SP,Tenidap-modulated proinflammatory cytokine activation of a monocyte cell line. J Immunol 1995; 154: 5384-90
46. Miltenburg AMM, Dolhain RJEM, de Kuiper R, et al, Tenidap inhibits T-cell proliferation, cytokine production and the induction of mRN A encoding TNF and IFN-gamma (abstract]. Arthritis Rheum 1994; 37: S384
47. Laliberte R, Perrigan XD, Svensson L, et al, Tenidap modulates cytoplasmic pH and inhibits anion transport in vitro. 2. Inhibition of IL1 production from ATP-treated monocytes and macrophages. J Immunol 1994; 153: 2168-79
48. Conti P, Reale M, Barbacane RC, et al. Effect of tenidap on CD3, CD4 and CDS expression and IL1 and LB4 secretion in PBMC. Biochem Cell Biol 1994; 72: 397-402
49. Sack U, Kühn H, Ermann J, et al, Synovial tissue implants from patients with rheumatoid arthritis cause cartilage destruction in knee joints of SCID.bg mice. J Rheumatol 1994; 21: 10-6
50. Bouma MG, Stad RK, van den Wildenberg FAJM, et al. Differential regulatory effects of adenosine on cytokine release by activated human monocytes. J Immunol 1994: 153: 4159-68
51. Prabhakar U, Brooks DP, Lipshlitz D, et al, Inhibition of LPSinduced TNF alpha production in human monocytes by adenosine ( A(2)) receptor selective agonists. Int J Immunopharmacol 1995; 17: 221-4
52. Rosengren S, Bong GW, Firestein GS, Anti-inflammatory effects of an adenosine kinase inhibitor: decreased neutrophil accumulation and vascular leakage. J Immunol 1995; 154: 5444-51
53. Thiel M, Acting via A2 receptor, adenosine inhibits the production of TNFa of endotoxin stimulated PMN. J Lab Clin Med 1995; 126: 275-82
54. Sommer N, Loschmann PA, Northoff GH, et al, The antidepressant rolipram suppresses cytokine production and prevents autoimmune encephalomyelitis. Nature Med 1995; 1: 244-8
55. Landman D, Sarai A. Sathe SS. Use of pentoxifylline therapy for patients with AIDS-related wasting: pilot study. Clin Infect Dis 1994; 18: 97-9
56. Maksymowych WP, Avinazubieta A, Luong MH, et al, An open study of pentoxifylline in the treatment of severe refractory rheumatoid arthritis. J Rheumatol 1995; 22: 625-9
57. Eugui EM, Delustro B, Rouhafza S, et al, Coordinate inhibition by some antioxidants of TNF alpha, 1L-1 beta, and IL-6 production by human peripheral blood mononuclear cells. Immunosuppressive Antiinflammatory Drugs 1993; 696: 181-4
58. Eugui EM, Delustro B, Rouhafza S, et al, Some antioxidants inhibit, in a co-ordinate fashion, the production of tumor necrosis factor-alpha, IL-beta, and IL-6 by human peripheral blood mononuclear cells. Int Immunol 1994; 6: 409-22
59. Zhang HB, Spapen H, Nguyen DN, et al, Protective effects of N-acetyl-L-cysteine inendotoxemia. AmJ Physiol 1994; 266: H1746-54
60. Marchant A, Bruyns C, Vandenabeele P, et al, Interleukin-IO controls interferon-gamma and tumor necrosis factor production during experimental endotoxemia. Eur J Immunol 1994: 24: 1167-71
61. School LB, Albrecht H, Gallay P, et al, Cytokine regulation of TNF-alpha mRNA and protein production by unprimed macrophages from C57BI6 and NZW mice. J Leukocyte Biol 1994; 56: 514-20
62. Chernoff AE, Granowitz EV, Shapiro L, et al, A randomized, controlled trial of IL-10 in humans: inhibition of inflammatory cytokine production and immune responses. J Immunol 1995; 154:5492-9
63. Moreira AL, Sampaio EP, Zmuidzinas A, et al, Thalidomide exerts an inhibitory action on TNFa by enhancing mRNA degradation. J Exp Med 1993: 177; 1675-80
64. Revuz J, Guillaume J, Janier M, et al. Crossover study of thalidomide vs placebo in severe recurrent aphthous stomatitis. Arch Dermatol 1990: 126:923-7
65. Guttierrez-Rodriguez O, Starusla-Bacal P, Guttiérrez-Monter O, Treatment of refractory RA: the thalidomide experience. J Rheumatol 1989; 16: 156-63
66. Mohler KM, Sleath PR. Fitzner JN. et al. Protection against a lethal dose of endotoxin by an inhibitor of tumour necrosis factor processing. Nature 1994; 370: 218-20
67. Gearing AJH, Beckett P, Christodowlow M. et al. Matrix metalloproteinases and processing of pro-TNF-oc. J Leukocyt Biol 1995:57: 774-7